Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Karyopharm

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

- PMLiVE

EC launches €150m brain research fund

It will cover key areas of research, such as mental disorders, pain, epilepsy and paediatric conduct disorders

- PMLiVE

Biogen submits haemophilia drug for US approval

Step forward for its partnership with Swedish Orphan Biovitrum

- PMLiVE

Biogen Idec drops ALS drug dexpramipexole

Fails to achieve efficacy in phase III trial

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Biogen Idec licenses antisense drugs from Isis in $630m deal

Gains neurological and neuromuscular disorder projects

- PMLiVE

Treating the brain with software

Clinical trials of game-like software designed to re-programme the brain and tackle some of the most intractable symptoms of schizophrenia could usher in a new way to treat a range...

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links